Tag Archives: Clovis Oncology

← Older posts Newer posts →

Cyteir Bags $29M to Tap “Self Destruct” in Cancers, Immune Diseases

The rapid growth of cancer cells actually damages them, leading them to rely on internal repair mechanisms. Scientists are finding ways to disrupt these repair features to fight the disease, and their research is leading to a growing crop of startups. Among them: Cambridge, MA-based Cyteir Therapeutics, which has just raised $29 million from Venrock, […]

Posted in Boston, Boston blog main, Boston top stories, Boulder/Denver blog main, National blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Cyteir Bags $29M to Tap “Self Destruct” in Cancers, Immune Diseases

Moderna Ends “Venture” Experiment, Dissolves Four Startups

Moderna Therapeutics, the high-flying private company with a $1 billion war chest, is reversing course. Three years ago, it decided to hatch startups as wholly-owned subsidiaries, all working on different aspects of its unproven biomedical technology called messenger RNA. Moderna announced today that it is ending the experiment. It is dissolving the four startups, or […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on Moderna Ends “Venture” Experiment, Dissolves Four Startups

On Drug Pricing: FDA Backs Up Its Calls for Increased Competition

FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. Recently, the agency he oversees took some unusual steps to back up those statements with action. Last week, the FDA approved the use […]

Posted in Boston Xcon, Boulder/Denver Xcon, Detroit Xcon, Indiana Xcon, National Xcon, New York Xcon, Raleigh-Durham Xcon, San Diego, San Diego Xcon, San Francisco Xcon, Seattle Xcon, Texas Xcon, Wisconsin Xcon | Tagged , , , , , , , , , , , , , , | Comments Off on On Drug Pricing: FDA Backs Up Its Calls for Increased Competition

Tesaro Cashes In Again on PARP Blocker With $100M Takeda Deal

Tesaro rode the clinical success of a cancer drug called niraparib (Zejula) to a three-fold increase in value over the past year. Today it’s cashed in the drug again, striking a licensing deal with Japan’s Takeda Pharmaceutical. Takeda is paying Waltham, MA-based Tesaro (NASDAQ: TSRO) $100 million up front for the rights to niraparib in […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , | Comments Off on Tesaro Cashes In Again on PARP Blocker With $100M Takeda Deal

Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More

All eyes are on the nation’s capital this week, where the Senate released its version of the American Health Care Act (now called the Better Care Reconciliation Act) and the White House worked on an executive order to address drug prices. No one knows how to pay for high-priced medicines that could bring long-term relief […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More

Repare Nabs $68M To Find Synthetic Lethal Cancer Targets Beyond PARP

The concept of synthetic lethality has been around for decades, but only recently has it been exploited for cancer therapy. The idea is to hit cancer cells in at least two places at once; the trick is to find the right combination of genetic mutations that make the cells vulnerable. The newest company aiming to […]

Posted in Boston, Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, National blog main, National top stories, New York blog main, New York top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Repare Nabs $68M To Find Synthetic Lethal Cancer Targets Beyond PARP

New Ovarian Cancer Data Suggests Larger Role For Top Clovis Drug

Clovis Oncology received a short-cut approval from the FDA last year for its ovarian cancer drug that treats women with the common BRCA genetic mutation. Clovis (NASDAQ: CLVS) said Monday it now has evidence that the drug, rucaparib (Rubaca), can treat a wider swath of patients, and it will ask the FDA for approval this […]

Posted in Boston blog main, Boston top stories, Boulder/Denver, Boulder/Denver blog main, Boulder/Denver top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on New Ovarian Cancer Data Suggests Larger Role For Top Clovis Drug

Tesaro’s Ovarian Cancer Drug Gets FDA Nod, No Diagnostic Needed

An ovarian cancer drug from Tesaro has won FDA approval ahead of schedule, adding a third treatment to a new group of therapies that work by blocking a process that tumors use to repair themselves. Waltham, MA-based Tesaro (NASDAQ: TSRO) says the FDA approved its drug niraparib (Zejula) drug as a maintenance therapy for women […]

Posted in Boston, Boston blog main, Boston top stories, Boulder/Denver blog main, National blog main | Tagged , , , , , , , , , , | Comments Off on Tesaro’s Ovarian Cancer Drug Gets FDA Nod, No Diagnostic Needed

Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More

You’ve probably seen the Internet memes. “When 2016 started, I looked like this. [Insert picture of young Leo DiCaprio.] Now I look like this. [Leo, with mountain beard, after mud-wrestling with a grizzly in The Revenant.]” In life science terms, let’s just say all our telomeres feel a lot shorter than 12 months ago. The […]

Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More

Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug

Slowly but surely, a new group of drugs known as “PARP” inhibitors are starting to become fixtures in the regimens for women with ovarian cancer—and perhaps more. With the approval of a drug called rucaparib (Rubraca) from Clovis Oncology, two have now been approved since 2014—and a third, from Waltham, MA-based Tesaro (NASDAQ: TSRO), could […]

Posted in Boston blog main, Boulder/Denver, Boulder/Denver blog main, Boulder/Denver top stories, National blog main, New York blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug← Older posts Newer posts →